Vorinostat

Recurrent Non-Hodgkin Lymphoma

M.D. Anderson Cancer CenterSmall moleculePhase 2Active

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 53/ 100
Competitive Position: 95/ 100

Competitive context

13 Active assets in the Recurrent Non-Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Nivolumab University of Pittsburgh	Phase 2/3	BBB
Fludarabine Marcela V. Maus, M.D.,Ph.D.	Phase 3	BBB
Cediranib Mayo Clinic	Phase 2	BB
5-azacytidine National Cancer Institute (NCI)	Phase 2	BB
Tazemetostat SWOG Cancer Research Network	Phase 2	BB

View all 21 →

Same molecule, other indications

Vorinostat is also rated in:

Non-Small-Cell Lung CarcinomaDormant

BB

Indicative ·

71 / 100

Hodgkins lymphomaDormant

BB

Indicative ·

68 / 100

acute myeloid leukemia with 11q23 abnormalitiesDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.